Labor shortages and rising costs aren’t expected to limit healthcare deal volume in 2022, according to a new survey of more than 300 industry executives.
The survey findings, published this week by advisory firm KPMG, showed that 70% of healthcare and life sciences executives expect increased M&A activity in 2022 — with more than half of them saying they plan to do at least 10% more deals in 2021.